^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SYN101

    i
    Other names: SYN101
    Associations

    News

    Trials
    Company:
    Synthis Therap
    Drug class:
    TGFβ-targeted antibody-drug conjugate
    Associations

    News

    Trials
    over3years
    SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression and drives tumor clearance in vitro and in vivo (SITC 2022)
    Safer, more effective TGF-b therapies, like SYN101, will provide novel monotherapy options for cancer patients. Additionally, because TGF-b sets the overall threshold for T cell activation, SYN101 could improve the efficacy of a variety of therapies, including checkpoint inhibition, radiation and NK/CAR-T therapies.
    Preclinical • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    IFNG expression
    |
    SYN101